289039-21-0 Usage
General Description
3-Bromo-5-Iodobenzonitrile is a chemical compound with the molecular formula C7H3BrIN. It is a pale yellow crystalline solid that is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. 3-Bromo-5-Iodobenzonitrile is a versatile building block in organic chemistry due to its high reactivity and ability to undergo various chemical reactions such as nucleophilic substitution, Suzuki coupling, and transition metal-catalyzed cross-coupling reactions. Additionally, 3-Bromo-5-Iodobenzonitrile is known for its ability to participate in the synthesis of various heterocyclic compounds, making it an important reagent in the pharmaceutical industry. Due to its unique chemical properties, this compound is widely used in research and industrial applications as a key component in the production of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 289039-21-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,9,0,3 and 9 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 289039-21:
(8*2)+(7*8)+(6*9)+(5*0)+(4*3)+(3*9)+(2*2)+(1*1)=170
170 % 10 = 0
So 289039-21-0 is a valid CAS Registry Number.
289039-21-0Relevant articles and documents
Design and Optimization of 3′-(Imidazo[1,2- a]pyrazin-3-yl)-[1,1′-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors
Mo, Cheng,Zhang, Zhang,Li, Yupeng,Huang, Minhao,Zou, Jian,Luo, Jinfeng,Tu, Zheng-Chao,Xu, Yong,Ren, Xiaomei,Ding, Ke,Lu, Xiaoyun
, p. 379 - 384 (2020/01/31)
DDR1 is considered as a promising target for cancer therapy, and selective inhibitors against DDR1 over other kinases may be considered as promising therapeutic agents. Herein, we have identified a series of 3′-(imidazo[1,2-a]pyrazin-3-yl)-[1,1′-biphenyl]
Oxidation of aldehydes to nitriles with an oxoammonium salt: Preparation of piperonylonitrile
Kaetzel, Nathaniel D.,Kelly, Christopher B.,Lambert, Kyle M.
, p. 294 - 313 (2020/11/09)
-
